Living Cell Technologies Ltd
ASX:LCT

Watchlist Manager
Living Cell Technologies Ltd Logo
Living Cell Technologies Ltd
ASX:LCT
Watchlist
Price: 0.012 AUD Market Closed
Market Cap: 19.6m AUD

Living Cell Technologies Ltd
Cash from Operating Activities

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Living Cell Technologies Ltd
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
Living Cell Technologies Ltd
ASX:LCT
Cash from Operating Activities
-AU$2m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Opthea Ltd
ASX:OPT
Cash from Operating Activities
-$158.6m
CAGR 3-Years
-31%
CAGR 5-Years
-95%
CAGR 10-Years
-41%
Mesoblast Ltd
ASX:MSB
Cash from Operating Activities
-$50m
CAGR 3-Years
9%
CAGR 5-Years
0%
CAGR 10-Years
N/A
CSL Ltd
ASX:CSL
Cash from Operating Activities
$3.6B
CAGR 3-Years
11%
CAGR 5-Years
7%
CAGR 10-Years
10%
Telix Pharmaceuticals Ltd
ASX:TLX
Cash from Operating Activities
AU$27.9m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
PYC Therapeutics Ltd
ASX:PYC
Cash from Operating Activities
-AU$51.6m
CAGR 3-Years
-33%
CAGR 5-Years
-55%
CAGR 10-Years
-35%
No Stocks Found

Living Cell Technologies Ltd
Glance View

Market Cap
18.7m AUD
Industry
Biotechnology

Living Cell Technologies Ltd. is a biotechnology company, which engages in the development of treatments for implanting healthy living cells to replace or repair diseased or damaged organs for life threatening diseases. The company is headquartered in Melbourne, Victoria. The company went IPO on 2004-09-01. The firm is focused on discovering and developing treatments for conditions, such as Parkinson's disease, diabetes, obesity and migraine. The firm's product pipeline consists of LP-003 for anti-obesity, LC-002 for migraine treatment and NTCELL for Parkinson's disease. Its Long-acting Pramlintide, LP-003 is a peptide drug that reduces caloric intake targeting obesity and it is also used for the treatment of diabetes. LC-002, is a receptor blocker targeting calcitonin gene-related peptide (CGRP), a neuropeptide hormone found in the nervous system. NTCELL is an alginate coated capsule containing clusters of neonatal porcine choroid plexus cells targeting Parkinson's disease. NTCELL's choroid plexus cells are coated with LCT's IMMUPEL technology to protect them from attack by the immune system. The company has completed Phase I/IIa clinical trial and phase IIb trials for mid- to late-stage Parkinson's disease.

LCT Intrinsic Value
Not Available

See Also

What is Living Cell Technologies Ltd's Cash from Operating Activities?
Cash from Operating Activities
-2m AUD

Based on the financial report for Jun 30, 2023, Living Cell Technologies Ltd's Cash from Operating Activities amounts to -2m AUD.

What is Living Cell Technologies Ltd's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 1Y
3%

Over the last year, the Cash from Operating Activities growth was 3%.

Back to Top